CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $298 | $389 | $212 | $923 |
| Short-Term Investments | $1,606 | $1,304 | $1,603 | $1,456 |
| Receivables | $25 | $200 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $14 | $38 | $38 |
| Total Curr. Assets | $1,937 | $1,908 | $1,853 | $2,418 |
| Property Plant & Equip (Net) | $278 | $306 | $321 | $312 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $2 | $53 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $27 | $14 | $16 | $22 |
| Total NC Assets | $305 | $321 | $390 | $334 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2,242 | $2,230 | $2,243 | $2,752 |
| Liabilities | – | – | – | – |
| Payables | $15 | $38 | $27 | $15 |
| Short-Term Debt | $17 | $16 | $16 | $12 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $4 | $4 | $0 | $1 |
| Other Curr. Liab. | $51 | $51 | $78 | $92 |
| Total Curr. Liab. | $88 | $109 | $121 | $120 |
| LT Debt | $206 | $223 | $228 | $213 |
| Deferred Rev, NC | $12 | $14 | $12 | $12 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $1 | $6 | $7 |
| Total NC Liab. | $222 | $238 | $246 | $233 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $206 | $223 | $228 | $213 |
| Total Liabilities | $310 | $347 | $368 | $352 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3 | $2 | $2 | $2 |
| Retained Earnings | -$1,366 | -$1,000 | -$846 | -$196 |
| AOCI | $2 | $2 | -$16 | -$5 |
| Other Equity | $3,293 | $2,878 | $2,735 | $2,598 |
| Total Equity | $1,932 | $1,883 | $1,875 | $2,399 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $2,242 | $2,230 | $2,243 | $2,752 |
| Net Debt | -$75 | -$151 | $32 | -$698 |